Trellus Health Share Discussion Threads

[wan] 13/2/2023 09:34

I meant to post this article at the weekend, which aligns quite well with the progress Trellus has recently made. This article implies there is much more to come (and it looks like there could be more to come from Trellus) -

Using a Digital Doorway for Behavioral Health Support in 2023

Behavioral health will continue to take center stage in 2023. It is critical that industry stakeholders collaborate to identify critical mental health needs and leverage available technology to produce meaningful change.
By PETER STRIMAITIS

Feb 10, 2023

As the unpredictability of mental health services persists, here are three trends to watch for in 2023:

Digital expansion

For the past two years, the behavioral health industry has evolved tremendously to adapt to current consumer demands. Companies shifted all counseling to online sessions, providing more convenient care and improving care coordination. Virtual appointments are now easier for people to schedule and attend, remote monitoring improves chronic condition management for numerous conditions, telemedicine drastically decreases costs, and a familiar environment is proven to have a positive effect on patient outcomes.

Organizations also expanded the breadth of their services, branching out into less conventional territories. Increased accessibility allows organizations to address other issues such as population health and health equity. Moving forward, care models will continue to deviate from traditional models to include more digital options and provide a more consumer-friendly experience for behavioral health care.

Moreover, the current trend of employee benefit expansion will carry on. More organizations will develop employee assistance programs (EAPs) that encompass an integrated suite of offerings instead of the historically accepted few. Companies will begin to add more mental health-related services to their existing programs. These extensions should include adding health screenings, health coaching, teletherapy, and other digital tools that comprise a “digital doorway.”

Full article -

[wan] 13/2/2023 07:55

With today's news, that now completes 3 of contracts highlighted in Trellus' Half-year Report -

Significant progress with advancing B2B2C model
I am very pleased to report that, despite the longer lead times in the B2B2C contracting process as previously reported in December 2021, we have made significant progress in advancing a number of conversations with payers , such as regional and national health plans, employers, health systems, GI provider networks, and pharmaceutical companies. Whilst we have launched our D2C model, we remain focused on our B2B2C offering which provides better quality patient outcomes at lower costs to health plans and employers.

We are in productive conversations with two health plans, having entered late-stage discussions with one and starting the due diligence process with another; we are in the final contracting phase for a New York Medicaid plan and we have two further contracts, one with a large NY State employer and the other with a NY State Provider to support members of a large NY labor union, which we expect to be signed soon.

We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform.

Expansion into Irritable Bowel Syndrome (IBS) for comprehensive GI solution



Hopefully we will see continued execution in IBS expansion and the pharma discussions/contracts that were also referred to, not to mention "The Company expects to provide a more detailed trading update by early February 2023."

[wan] 02/2/2023 08:57

A couple of excerpts from the Half-year Report -

"Following Our initial focus was on IBD, a lifelong chronic disease plagued by mismanagement, improper treatment, high costs and rates of anxiety, depression and emergency healthcare utilization. However last year , we initiated research into versioning Trellus Resilience Training into IBS, another chronic GI condition that has significant similarities with IBD from a symptom burden and emotional perspective. IBS however has a much higher population prevalence than IBD, impacting c. 10% of the US population (c. 30m patients for IBS compared to c. 3m for IBD). Whilst the annual healthcare spend on IBS is higher at c. $61 bn (IBD c $25 bn), this is significantly lower than IBD on a "per patient" basis.

Originally, we had expected to launch the Trellus Method for IBS in H1 2023, however using existing resources we have accelerated the launch of our IBS application which is now expected at the start of Q1 2023, when we will be offering patients a comprehensive GI solution covering both IBD and IBS. We also believe our solution can be used across many other chronic conditions to deliver meaningfully improved healthcare outcomes as well as reducing expensive, unplanned care, such as emergency department visits and hospitalisations."


And from the 20th Dec 2022 update -

"The Company expects to provide a more detailed trading update by early February 2023."
(END)

I note that Trellus has now widened their offering to include IBS -

Digestive Health Support, Reimagined
Trellus Health supports and empowers people living with Crohn's disease, ulcerative colitis, and IBS. Using our clinically proven program, Trellus Health helps you manage your health and live a fuller life.


Trellus Health for Individuals with Irritable Bowel Syndrome -

[wan] 19/1/2023 08:53

The market is still unimpressed with Trellus, despite some positive news flow and change etc, but the market obviously wants more than a just a positive backdrop in terms of prospects.

To repeat: Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS.

I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. But the dynamics appear to be on the cusp of change with regard to pharma developments related to IBD.

From the Trellus Health Half-year Report -

"We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform."

Pharmaceutical competition looks set to increase, which may increase the attention, and intensify the ongoing discussions with Trellus -

January 17, 2023

Digesting 2022 and looking forward to 2023 in IBD therapeutics

The past year has seen quite a few new developments in inflammatory bowel disease therapy.

Other important developments to anticipate in 2023 include the introduction of as many as eight adalimumab biosimilars to the U.S. market, which almost certainly will drive the price of adalimumab down, and the potential approvals of subcutaneous Entyvio (vedolizumab, Takeda) and Inflectra (infliximab-dyyb, Celltrion) for the treatment of IBD.

These therapeutics have already been approved in multiple other regions including Europe. It will be interesting to see what effect the availability of the adalimumab biosimilars and subcutaneous vedolizumab and infliximab-dyyb will have on treatment algorithms, especially if the cost differences are significant.

I suspect it will take time for us to “digest” all these new developments, and the publication of real-world experiences with these new agents will help shape our clinical practice. Here’s looking to 2023!

Full article -

Food for thought: Dr. Dubinsky is co-founder and equity owner in a MiTest Health, which received a licensing fee from Takeda for CDPATH. Dr. Dubinsky has received compensation from both Takeda Pharmaceutical and Prometheus Laboratories as a consultant. In addition to Takeda, Dr. Dubinsky also serves as a paid consultant for other pharmaceutical companies that develop and/or manufacture treatments for inflammatory bowel disease (IBD). Dr. Dubinsky is co-founder and equity owner of two start-up companies involved in IBD healthcare, Trellus Health and GoDoRun.

[wan] 04/1/2023 09:28

A worthy and thought-provoking read -

10 Key Medtech Themes for 2023
We expect 2023 to be a pivotal year for the industry, as the accelerated acceptance of virtual care and demographic trends, such as an aging population, increasing chronic illnesses and healthcare worker shortages, sustain demand for medtech-enabled solutions.
By VINITA KAILASANATH AND SORA PARK

Jan 3, 2023

[wan] 20/12/2022 07:36

Todays RNS confirms the cash position at year end is slightly better than expected and reflecting the Company's close control of cash, which is close to my previous estimate -

"Quiet here with the shares trading, by my estimate (cash at year-end in Dec equating to c10p per share), at a relatively small premium to expected cash levels and which provide a cash runway into 2025 which is based on managements conservative assumptions only."

Further updates to follow -

The Company expects to provide a more detailed trading update by early February 2023.

The Company expects to provide further commentary on its business development opportunities when it issues its further update in early 2023.

Recall also the following from the Half-ear Results -

Originally, we had expected to launch the Trellus Method for IBS in H1 2023, however using existing resources we have accelerated the launch of our IBS application which is now expected at the start of Q1 2023, when we will be offering patients a comprehensive GI solution covering both IBD and IBS. We also believe our solution can be used across many other chronic conditions to deliver meaningfully improved healthcare outcomes as well as reducing expensive, unplanned care, such as emergency department visits and hospitalisations.
(END)

I my view, with the shares trading at 11p, the upside potential is meanly priced in!

[wan] 07/12/2022 07:46

Above link sorted

[wan] 07/12/2022 07:44

Staying with the pharma angle -


1 day ago

Day 1 at the #AIBD conference, and there was no shortage of fantastic speakers!

Our CEO and cofounder Dr. Marla Dubinsky
presented at the Pediatric Track Breakout session, leading a discussion called “Brave New World: Navigating and Positioning the Growing Armentarium of Biologics for Pediatric Patients”.

Within her presentation, she discussed the fundamental principles in the approach to positioning IBD therapies and the importance of personalization, what drives the need for different therapies, switching from an empiric approach to a more biologic approach, and the relative efficacy of biologics for induction and maintenance therapies for Crohn’s disease and ulcerative colitis.


For more on the above from the AIBD conference -

Marla Dubinsky, MD, on Brave New World: Positioning Biologics for Pediatric Patients With IBD

Dr Dubinsky reviews her keynote presentation on the use of newer biologics with pediatric patients with inflammatory bowel diseases.

[wan] 07/12/2022 07:39

Very well deserved!
Trellus CEO has been awarded the Sherman Prize, the video contained within the link is worth watching too -

14hrs ago
Congratulations to our CEO and cofounder, Dr. Marla Dubinsky on receiving the Sherman Prize this morning at the #AIBD Conference. Your passion for improving patient lives and innovative approaches to #IBD medicine are truly admirable. We are truly fortunate to have such an inspirational leader at our organization, and congratulations again for this tremendous honor!



2022 PIONEERS
Recipients stories -
Going above and beyond in the fight to overcome
Crohn's disease and ulcerative colitis.

[wan] 06/12/2022 09:43

Quiet here with the shares trading, by my estimate (cash at year-end in Dec equating to c10p per share), at a relatively small premium to expected cash levels and which provide a cash runway into 2025 which is based on managements conservative assumptions only.

I note that Trellus has updated/revamped their website -


Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS.

I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. A reminder -

"We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform."

[wan] 11/11/2022 07:29

Medtech execs ‘rethink’ long-term strategies as care settings shift: Accenture report
Published Nov. 10, 2022

Dive Brief:
More than 75% of surveyed medtech executives expect expanding care settings and delivery models to “significantly re-orient their company’s long-term strategy.”

Dive Insight:
The COVID-19 pandemic accelerated shifts that were already underway in the industry, notably moves from in-person to virtual interactions and from hospital to ambulatory care centers. According to Accenture’s report, which is based on the survey and interviews with 30 digital health senior executives and C-suite leaders, the shift in where care happens is only just beginning.

“We estimate that 80% to 90% of chronic and behavioral care can shift to virtual. It means that providers are able to work to the full extent of their medical training, rather than burning time on more menial tasks,” an unidentified executive at AdvaMed’s Digital Health Center of Excellence said in the report.

The surveyed and interviewed executives expect to transform their businesses in response to the shifts in how care is delivered. While traditional products still account for most sales, the executives see the expansion of care to new settings as part of their growth strategies. Accenture cited the use of diagnostic tests at physician’s offices or at home, rather than at large hospital labs, as an example of the changes.

Full article -

The above sits well with the recent news from Trellus -

LONDON, U.K. AND NEW YORK, U.S. (19 October 2022): Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, personalized resilience-driven self-management solution for chronic health conditions at their intersection with mental health, announces that the Trellus Resilience Training and Self-Management Solution for Inflammatory Bowel Disease (the "Trellus IBD program") is now available on GI OnDemand, gastroenterology's leading multidisciplinary virtual integrated care platform .

GI OnDEMAND, a joint venture between the American College of Gastroenterology ("ACG") and Gastro Girl, Inc., now offers the Trellus IBD program, to all GI OnDEMAND and ACG members nationwide to coordinate and deliver personalized behavioral, emotional and nutritional support for their IBD patients remotely via digital solutions, and access to an expert resilience team via telehealth . The Trellus IBD program will be the only resilience driven self-management training solution offered via this platform to over 16,000 gastrointestinal ("GI") professionals across the US for the benefit of the millions of patients they collectively serve.

[mikemine1] 10/11/2022 19:53

One very attractive aspect of the business model, as far as I can see, is that, once a patient comes on to the programme, they stay for a very long time, possibly for life. This means that TRLS have only one sale to make, if you like, to acquire a very long term pipeline of revenue. It's cumulative and should not be a linear growth as more and more clinicians should join the band of referrers.

This could be very big but patience will be required.

All my own opinion of course.

[londonmarket] 25/10/2022 12:15

I have Crohn's Disease. I will be talking about Trellus to all clinicians I can. The NHS IBD Team who manage me are overwhelmed, one consultant -> 3 nurses for a massive urban area of a disease which is only increasing in prevalence.

[mikemine1] 21/10/2022 04:17

Think of markets, link-ups, contracts etc. all you like but, for me, the big number here is TRLS has said they only need 8,000 patients to break even. Now look at all the potential patients the fore mentioned access points open up to Trellus. Do you think that number will come out of those tie-ups? To me it's a no brainer that the 8.000 will be exceeded and that means profit. The only question for me is when?

Ramp over......................for now.

[wan] 19/10/2022 07:32

With today's announcement the transition to meaningful revenue generation appears well underway, but there could be more to come if the late stage discussions with two large pharmaceutical companies result in partnerships/contracts.

With a market cap that's still only marginally higher than cash, there should still be plenty of upside for the rerating to continue.

[robin_lemer] 18/10/2022 10:23

The last presentation by the management is a mus to listen to. Major points:

The biggest group of gastroenterologists in the US will announce on 22/23 October that the first port of call for people with IBS or IBD is Trellus. There are over 32 million people in US with one of the conditions .Their new CEO is a most respected docotr in this field.They also said there will be many positive announcements going forward. Additionally they have reduced their burn rate considerably. I like many on this site am a holder from when they first floated and therefore am holding paper losses however have bought more shares at 9.5p and 13p. See the presentation through Investor meet site well worth it

[theblackbaron] 04/10/2022 20:48

Making loads

[shanew48] 04/10/2022 18:42

“You should be warned off this site“

What does one have to do to be deemed unsuitable for THIS site! Lol it’s like all the mentally ill and adult virgins in the UK got together and asked “where can we spend our days posting messages to each other?” My god, this place makes LSE look like royalty!

[shanew48] 04/10/2022 18:18

Hopefully back to 65p very soon here you would presume.

[shanew48] 04/10/2022 16:48

This has much further to go this week? 20p + by the end of this week?

[mikemine1] 03/10/2022 18:18

Thanks James.

[james188] 03/10/2022 18:16

mikemine1 Sign up to the (free) InvestorMeetCompany website. The presentation can be accessed there.